This project has been flagged by a community member as inappropriate due to reason below.*

Expert Interview

Slingshot members are talking to an expert! The topic is:

A discussion of DREAMM-5 Study (low-dose Blenrep + nirogacestat) in r/r Multiple myeloma

Ticker(s): SWTX, GSK

Who's the expert?

Institution: Washington University St. Louis

  • Professor Department of Medicine Oncology Division Bone Marrow Transplantation & Leukemia at WUSTL
  • Principal investigator on several national clinical trials looking at strategies to improve the outcome of patients with multiple myeloma, acute myeloid leukemia, and myelodysplastic syndromes.
  • Currently treats ~300 patients with multiple myeloma, 25 patients with AML, 10 patients with CMML, and ~15 patients per month with AL Amyloidosis.

Interview Questions
Q1.

Please describe your specialty and details about your clinical practice.

Added By: user1ae2bf5f
Q2.

How many patients with R/R Multiple Myeloma do you treat?  At what line of treatment do patients show up to your practice? 

Added By: user1ae2bf5f
Q3.

-Have you used Blenrep in clinical practice based on its current approval as a monotherapy so far? And if so, in what line of treatment?

Added By: user1ae2bf5f
Q4.

When you think about safety and efficacy of blenrep, how does it compare across the landscape of treatments now available and in late stage development, and where does it currently fit into the picture?  

Added By: user1ae2bf5f
Q5.

Other Blenrep real-world use questions:

Are there difficulties providing it? Logistical or otherwise.     
How did your patients (if any) do on the drug? Did they benefit?
How do you characterize the duration of response?  Does it match the clinical trial numbers which were used for the FDA approval?   

Added By: user1ae2bf5f
Q6.

-Could you talk about the gamma secretase inhibitor, Nirogacestat, and its role in terms of processing BCMA and whether this might bring something to the table in treatment of MM in combination with something like Blenrep.

Added By: user1ae2bf5f
Q7.

Could cleaved soluble BCMA released exported out of the cell and into the circulation be limiting efficacy of BCMA agents like Blenrep?
Or do you think the lack of sufficient levels of cell surface (membrane-bound) BCMA is the underlying factor limiting the therapeutic window of Blenrep as a BCMA ADC?

Added By: user1ae2bf5f
Q8.

Are there unintended consequences you might anticipate from increasing the surface expression of BCMA or otherwise by inhibiting gamma secretase, which also cleaves other proteins besides BCMA? Or do you think this MOA has a compelling rationale?

Added By: user1ae2bf5f
Q9.

In terms of the trial data, in later relapse patients like they are testing here (in DREAMM-5), how much duration of response is sufficient to demonstrate that the combo is active?

Added By: user1ae2bf5f
Q10.

More generally about DREAMM5 - What are you hoping to see in this trial?

Added By: user1ae2bf5f
Q11.

When you will see the results of this combo at ASCO, what is the bar for comparison? Which treatment option sets the standard here and what is that bar in this particular setting for efficacy and safety?

Are you looking at whether they can improve the profile of Blenrep with a lower dose, for better safety, with efficacy that matches Blenrep alone?
Or does Blenrep have such a small role currently that the real bar is for real efficacy as compared to other agents, approved or near approval?

What AEs caused by Blenrep are most pressing, and what would position this combination favorably or unfavorably depending on what is shown?

Added By: user1ae2bf5f
Q12.

What kind of result could they show here that would make you rethink the role of Blenrep and assign it higher priority as a combo with GSI once it is approved?  What improvements specifically to safety, percentage wise or by grade that will make the agent more compelling with its current level of efficacy?
Or would efficacy also need to improve and if so, to what level?  (ORR, DOR, etc)

Added By: user1ae2bf5f
Q13.

Did agents in late stage development such as BCMA-CD3 bispecifics already set a new bar and therefore does this combo need to match data from existing agents that are not yet approved but expected to be over the next few years?   What numbers would the combo need to match in your view?  

Added By: user1ae2bf5f
Q14.

Please contextualize the expectations of this data in light of BCMA CAR-T products.

Added By: user1ae2bf5f
Q15.

On a scale of 1-10, how excited are you about the upcoming ASCO Abstract 8019 of Blenrep + Nirogacestat?

Added By: user1ae2bf5f

Are You Interested In These Questions?

Slingshot Insights Explained

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.

Reason

*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.